Medigen, Inc.
Frederick, MD
Company facts
- FY2025 rankings
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Physical address
- 8420 Gas House Pike S, Frederick, MD 21701, USA
- Website
- medigen-usa.com
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $2,307,491 |
| FY2025 | $2,181,107 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $2,307,491 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| Saint Louis University | R01AI130190 | $6,200 |
Similar vendors
About the company
Medigen, Inc. NA Division, a for-profit corporate entity headquartered in Frederick, Maryland, develops live-attenuated vaccines and vaccine platform technologies for biodefense and emerging infectious disease threats as a prime recipient of federal research grants and contracts under non-set-aside competitive procurements. The vendor operates almost exclusively as a prime recipient (95% of recent awards) and holds no federal contract vehicle seats; all work flows through direct awards from the National Institutes of Health, primarily the National Institute of Allergy and Infectious Diseases.
Medigen's capability portfolio centers on vaccine development and clinical evaluation for Category B pathogens and biodefense threats. Recent representative work includes a $2.181 million definitive contract awarded by NIAID on September 23, 2025, for development of a Lassa fever vaccine through Phase 1 or 2 clinical trials, running through September 2030 under cost-no-fee pricing and place of performance in Frederick, Maryland. A cooperative agreement from NIAID awarded March 1, 2022, supported safety and immunogenicity testing of a novel live-attenuated V4020 vaccine for Venezuelan equine encephalitis, with clinical evaluation running through February 2027 and using Medigen's proprietary iDNA infectious clone platform to improve vaccine genetic stability and reduce reversion risk. Earlier work includes National Cancer Institute grants and Department of Agriculture National Institute of Food and Agriculture awards for related viral vaccine and diagnostic development.
Customer concentration is heavily skewed to NIAID within the broader HHS/NIH ecosystem. NIAID accounts for 10 awards carrying $3 million in combined potential value and represents 100% of the top-customer coverage by both award count and potential value; the National Cancer Institute and USDA NIFA together account for the remaining potential value. Activity has been sparse but steady — one award per year from 2018 to 2020, then a two-year gap, then two awards in 2025 — with only one award (combined potential value not detailed in source) facing ultimate completion within the next twenty-four months. Medigen subcontracts minimally; the source names one grant sub-award placed with Saint Louis University in January 2025 for recombinant protein and VLP-encapsidated RNA vaccine design and production supporting in vitro and animal model testing.
SBA capabilities narrative
Vaccine development, biotechnology services
Quick answers
Is Medigen, Inc. registered in SAM.gov?
Yes. Medigen, Inc.'s SAM.gov registration is active through April 22, 2027.
What is Medigen, Inc.'s CAGE code?
Medigen, Inc.'s CAGE code is 4XUZ4, and its Unique Entity ID (UEI) is MGLJHKGKWBL3.
How much has Medigen, Inc. received in federal contracts?
Federal contracts obligated $2,181,107 to Medigen, Inc. in fiscal year 2025 and $4,488,598 in fiscal years 2023 through 2027.
How does Medigen, Inc. rank among federal contractors?
Medigen, Inc. ranked #44 in PSC AN11 in FY2025.
What is Medigen, Inc.'s most recent federal award?
Medigen, Inc.'s most recent federal contract award is To develop a lassa fever vaccine (75N93025C00034), from National Institute of Allergy and Infectious Diseases (NIH), on September 23, 2025.
On GovTribe
See Medigen, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors